

DAFTAR PUSTAKA

1. American Cancer Society. Nasopharyngeal Cancer. American Cancer Society. 2013. p. 1–9. <https://www.cancer.org/cancer/nasopharyngeal-cancer.html> - Diakses Januari 2021.
2. Sinambela A, Djakaria H. Revolusi Teknik Radioterapi pada Karsinoma Nasofaring. *Radioter Onkol Indones*. 2018;9(1):20–8.
3. Pastor M, Pousa AL, Barco E del. SEOM Clinical Guideline in Nasopharynx Cancer. *Clin Transl Oncol*. 2017;1–5.
4. Jia W-H, Luo X-Y, Feng B-J. Traditional Cantonese Diet and Nasopharyngeal Carcinoma Risk : a Large-Scale Case-Control Study in Guangdong China. 2010;10(446):1–7.
5. Cao S-M, Simons MJ, Qian C-N. The Prevalence and Prevention of Nasopharyngeal Carcinoma in China. *Chin J Cancer*. 2011;30(2):114–9.
6. World Health Organization. Indonesia Source GLOBOCAN 2018. *Int Agency Res Cancer*. 2019;256:1–2. - Diakses Januari 2021.
7. Jayalie VF, Paramitha MS, Jessica. Profile of Nasopharyngeal Carcinoma in Dr . Cipto Mangunkusumo National Hospital. *eJKI*. 2016;4(3):156–62.
8. Handayani R, Dewi YA, Madani DZ. Prevalence of Nasopharyngeal Carcinoma Patients in Departement of ORL-HNS Hasan Sadikin General Hospital 2010 -2017. *Int J Nasopharyngeal Carcinoma*. 2020;2(01):01–3.
9. Faiza S, Rahman S, Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. *J Kesehat Andalas*. 2016;5(1):90–6.
10. Tang M, Lautenberger JA, Gao X. The Principal Genetic Determinants for Nasopharyngeal Carcinoma in China Involve the HLA Class I Antigen Recognition Groove. *PLoS Genet*. 2012;8(11):1–12.
11. Chijioke O, Azzi T, Nadal D, Munz C. Innate Immune Responses Against Epstein Barr Virus Infection. *J Leukoc Biol*. 2013;94:1185–90.
12. Liu Y, Dai J, Xu C. Greater Intake of Fruit and Vegetables is Associated with Lower Risk of Nasopharyngeal Carcinoma in Chinese adults: a case-control study. *Cancer Causes Control*. 2012;23(4):589–99.
13. Xue W-Q, Qin H-D, Ruan H-L. Quantitative Association of Tobacco Smoking with the Risk of Nasopharyngeal Carcinoma: A Comprehensive Meta-Analysis of Studies Conducted Between 1979 and 2011. *Am J Epidemiol*. 2013;178(3):325–38.
14. Rahman S, Budiman BJ, Subroto H. Faktor Risiko Non Viral Pada Karsinoma Nasofaring. *J Kesehat Andalas*. 2015;4(3):988–95.

15. Lang J, Hu C, Lu T. Chinese Expert Consensus on Diagnosis and Treatment of Nasopharyngeal Carcinoma: Evidence from Current Practice and Future Perspectives. *Cancer Manag Res.* 2019;11:6365–76.
16. Chen L, Mao Y-P, Xie F-Y. The Seventh Edition of the UICC / AJCC Staging System for Nasopharyngeal Carcinoma is Prognostically Useful for Patients Treated with Intensity-Modulated Radiotherapy from an Endemic Area in China. *Radiother Oncol.* 2012;104:331–7.
17. Mao Y-P, Tang L-L, Chen L. Prognostic Factors and Failure Patterns in Non-Metastatic Nasopharyngeal Carcinoma After Intensity-Modulated Radiotherapy. *Chin J Cancer.* 2016;35(103):1–10.
18. Hermansyah ML, Dharniyati W, Choridah L. Modalitas Imejing pada Karsinoma Nasofaring. *J Radiol Indones.* 2017;2(2):117–22.
19. Guo R, Mao Y-P, Tang L-L. The Evolution of Nasopharyngeal Carcinoma Staging. *Br Inst Radiol.* 2019;92:1–9.
20. Hu Y-C, Tsai K-W, Lee C-C. Which Nasopharyngeal Cancer Patients Need Adaptive Radiotherapy ? *BMC Cancer.* 2018;18(1234):1–8.
21. Yang H, Hu W, Wang W. Replanning During Intensity Modulated Radiation Therapy Improved Quality of Life in Patients with Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys.* 2013;85(1):48–54.
22. Wang F, Jiang C, Wang L. Different Risk Target Volumes for Nasopharyngeal Carcinoma Treated with Simultaneous Integrated Boost Intensity-Modulated Radiotherapy. *J Cancer.* 2020;11(17):5210–22.
23. Cetin ZE, Eyigor S, Ozturk K. Evaluation of the Effect of Various Radiotherapy Modalities on Swallowing Function in Patients With Nasopharyngeal Cancer. *Ear, Nose Throat J.* 2019;98(9):1–5.
24. FK UNAND. *Pedoman Umum Penulisan Studi Literatur.* Padang; 2020.
25. Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. *Int J Radiat Oncol Biol Phys.* 2012;82(1):327–33.
26. Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys.* 2004;58(3):682–7.
27. Pan X Bin, Chen KH, Huang ST, Jiang YM, Ma JL, Liang ZG, et al. Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma. *Oncotarget.* 2017;8(44):78096–104.
28. Moretto F, Rampino M, Munoz F, Ruo Redda MG, Reali A, Balcet V, et al. Conventional 2D (2DRT) and 3D conformal radiotherapy (3DCRT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal cancer treatment. *Radiol Med.* 2014;119(8):634–41.

29. Chen L, Zhang Y, Lai S, Li W, Hu W, Sun R, et al. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma. *Oncologist*. 2019;24(1):1–8.
30. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. *Radiother Oncol*. 2012;104(3):286–93.
31. Nagai H, Kim YH. Cancer Prevention from the Perspective of Global Cancer Burden Patterns. 2017;9(3):448–51.
32. Bangun HA, Simanjuntak AM. Karakteristik Penderita Kanker Nasofaring di RSUD Dr . Pirngadi Medan Tahun 2018. *Wahana Inov*. 2018;7(2):1–5.
33. Lin K, Huang W, Lin C, Jen Y, Lin C, Lo C, et al. Subsequent risk of nasopharyngeal carcinoma among patients with allergic rhinitis: A nationwide population-based cohort study. *Head Neck*. 2015;413–7.
34. Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000-2011. *Rosetta Stone for NPC: Genetics, viral infection, and other environmental factors*. Elsevier. 2012;22:107–16.
35. Santoso BS. Radioterapi pada Karsinoma Nasofaring. *J Chem Inf Model*. 2013;53(9):1689–99.
36. Hu C. Konsensus ahli Tiongkok tentang diagnosis dan pengobatan karsinoma nasofaring : bukti dari praktik saat ini dan perspektif masa depan. 2019;6365–76.
37. Shaw R, Beasley N. Aetiology and risk factors for head and neck cancer: United Kingdom National Multidisciplinary Guidelines. *J Laryngol Otol*. 2016;130(S2):S9–12.
38. Simo R, Robinson M, Lei M, Sibtain A, Hickey S. Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines. *J Laryngol Otol*. 2016;130(S2):S97–103.
39. Jawad H, Hodson NA, Nixon PJ. A review of dental treatment of head and neck cancer patients, before, during and after radiotherapy: Part 1. *Br Dent J*. 2015;218(2):65–8.
40. Jham BC, Freire ARDS. Oral complications of radiotherapy in the head and neck. *Braz J Otorhinolaryngol*. 2006;72(5):704–8.
41. Malikha ZN. Efek Radioterapi Kepala dan Leher terhadap pH Saliva. 2008;24–57.
42. Asroel HA. Penatalaksanaan Radioterapi pada Karsinoma Nasofaring. *USU Digit*. 2002;1–11.

43. Cox JD, Stetz JA, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). *Int J Radiat Oncol Biol Phys.* 1995;31(5):1341–6.
44. Baharudin A, Khairuddin A, Nizam A, Samsuddin AR. Evaluation of irradiated salivary gland function in patients with head and neck tumours treated with radiotherapy. *J Laryngol Otol.* 2009;123(1):108–13.
45. Sciubba james j, Goldenberg D. Oral complications of cancer therapy. *Oncol An Evidence-Based Approach.* 2006;7:175–83.
46. Eisburch A, Rhodus N, Rosenthal D et al. How should we measure and report radiotherapy-induced xerostomia? *Semin Radiat Oncol.* 2003;13(3):226–34.
47. Farsi NMA. Signs of oral dryness in relation to salivary flow rate, pH, buffering capacity and dry mouth complaints. *BMC Oral Health.* 2007;7:1–6.
48. Hendrata JH. Efek Radioterapi Kanker Kepala dan Leher Terhadap Jaringan Dalam Mulut. Vol. 11, *Meditek.* 2015. p. 29–35.
49. Vissink A, Jansma J, Spijkervet FKL, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. *Crit Rev Oral Biol Med.* 2003;14(3):199–212.
50. Yunus B. Efek samping terapi radiasi penderita kanker kepala dan leher pada kelenjar saliva. *J Dentomaxillofacial Sci.* 2008;7(1):57.
51. Deasy JO, Moiseenko V, Marks L, Chao KSC, Nam J, Eisbruch A. Radiotherapy Dose-Volume Effects on Salivary Gland Function. *Int J Radiat Oncol Biol Phys.* 2010;76:58–63.
52. Traktama DO, Sufiawati I. Oral mucositis severity in patient with head and neck cancer undergoing chemotherapy and/or radiotherapy. *Maj Kedokt Gigi Indones.* 2018;4(1):52.
53. Sufiawati I, Subita GP. Identifikasi dan Pengendalian Faktor Risiko Mukositis Oral Selama Radioterapi Kanker Nasofaring. *J Dent Indones.* 2013;15(2):155–62.
54. Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment. *CA Cancer J Clin.* 2001;51(5):290–315.
55. De Graeff A, De Leeuw JRJ, Ros WJG, Hordijk GJ, Blijham GH, Winnubst JAM. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. *Eur J Cancer.* 2001;37(3):332–9.